Climb Bio, Inc. - Common Stock (NQ:CLYM)

10.31 -0.52 (-4.80%)

Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Climb Bio, Inc. - Common Stock

Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug ↗

September 03, 2026

Climb Bio (NASDAQ:CLYM) presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being developed for IgA nephropathy, and said the results support advancing the program into an ongoing...

Via MarketBeat

Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect ↗

May 21, 2026

Climb Bio (NASDAQ:CLYM) outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright’s BioConnect Conference, with management emphasizing two biologic...

Via MarketBeat

Unusual volume stocks in Tuesday's session ↗

December 16, 2025

Let's have a look at what is happening on the US markets on Tuesday. Below you can find the stocks with an unusual volume in today's session.

Via Chartmill

Which stocks are moving on Monday? ↗

December 15, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Monday's session: top gainers and losers ↗

December 15, 2025

Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Let's take a look at the stocks that are in motion in today's session. ↗

December 12, 2025

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 20, 2025

Via Benzinga

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗

October 16, 2025

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.

Via Benzinga

This Celestica Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

October 16, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 04, 2025

Via Benzinga

Which stocks are moving after the closing bell on Friday? ↗

July 04, 2025

The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.

Via Chartmill

Top movers in Thursday's after hours session ↗

July 03, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

Friday's after hours session: top gainers and losers ↗

April 11, 2025

As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Friday's After-Market Session ↗

April 11, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 15, 2025

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.